|
ZNF395 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.19499998574702E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.45070000351555E-08 |
| Normal-vs-Stage2 |
2.0485999996378E-07 |
| Normal-vs-Stage3 |
6.73249999971759E-07 |
| Normal-vs-Stage4 |
1.6464799999949E-05 |
| Stage1-vs-Stage2 |
1.558380E-01 |
| Stage1-vs-Stage3 |
8.961800E-01 |
| Stage1-vs-Stage4 |
9.604400E-01 |
| Stage2-vs-Stage3 |
2.036600E-01 |
| Stage2-vs-Stage4 |
2.431000E-01 |
| Stage3-vs-Stage4 |
9.615400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.41059999528792E-08 |
| Normal-vs-AfricanAmerican |
1.730140E-02 |
| Normal-vs-Asian |
5.656000E-03 |
| Caucasian-vs-AfricanAmerican |
2.855800E-01 |
| Caucasian-vs-Asian |
1.494210E-01 |
| AfricanAmerican-vs-Asian |
9.871400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.79989999571362E-08 |
| Normal-vs-Female |
2.51189999911361E-08 |
| Male-vs-Female |
2.714800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.89070000012582E-07 |
| Normal-vs-Age(41-60Yrs) |
1.17440000002578E-06 |
| Normal-vs-Age(61-80Yrs) |
8.11460010297083E-10 |
| Normal-vs-Age(81-100Yrs) |
8.643400E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.291000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.487500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.530800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.047700E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.546200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.217600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.804400E-02 |
| Classical-VS-Follicular |
1.37639899477904E-11 |
| Classical-VS-Other |
2.494800E-01 |
| Classical-VS-Normal |
1.830490E-04 |
| Tall-VS-Follicular |
7.015100E-04 |
| Tall-VS-Other |
7.417600E-01 |
| Tall-VS-Normal |
1.62454000000034E-05 |
| Follicular-VS-Other |
2.627000E-01 |
| Follicular-VS-Normal |
1.626032641866E-12 |
| Other-VS-Normal |
6.657100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.18659987286196E-10 |
| Normal-vs-N1 |
2.57449999985226E-07 |
| N0-vs-N1 |
9.223600E-01 |
|
|
